City of Hope^® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, life-threatening diseases. Each spotlight features research-related news, such as recognitions, collaborations and the latest research defining the future of medical treatment.

A recent study led by researchers at the University of Arizona Cancer Center and Northern Arizona University found that Native American women were disproportionately affected by vaginal dysbiosis, a disruption in the balance of bacterial that increases the risk of human papillomavirus infection, which can cause cervical cancer.

Deubiquitinases (DUBs) are enzymes used by cells to trim protein modifications made from the protein ubiquitin, and thereby regulate proteins. Malfunctioning of DUBs could lead to diseases, including cancer and neurodegenerative disorders. A protein called USP53 has been recently linked with progressive familial intrahepatic cholestasis, a hereditary liver disease in children, yet its mechanism of action has remained elusive. While its sequence made it part of a deubiquitinase family, previous attempt to detect catalytic activity had remained inconclusive. Now, a team led by Malte Gersch, group leader at the Max Planck Institute of Molecular Physiology, together with researchers from the TU Dortmund University and the Erasmus University Medical Center in Rotterdam have decoded the mode of action of USP53 and its related enzyme called USP54. Scientists revealed that both enzymes remove specifically long polyubiquitin chains from proteins. They also identified the proteins that USP53 acts on that could be associated with the liver disease, thereby suggesting how targeted treatment for such diseases could be identified.

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.